אנו, במכון ויצמן למדע, עומדים מוכי תדהמה ונכלמים בראותנו את ממשלת ישראל מאיימת לרסק את כל תנאי הסף לקיום חברה אזרחית בריאה, ולפעול בניגוד לחוק והוראת בית המשפט. המהפכה המשפטית שמובילה ממשלת ישראל, מאיימת על הדמוקרטיה ועל ערכי החופש העומדים בבסיס הגדרתה.

It is a historic day in the Cerebrovascular world! At WLNC2026| 22-24 2026 - Lisbon/Portugal, we presented the first in man cases of neuro HFOCT - and it surpassed all our expectations!!!

ENIRCH trial data presented at the #ESOC2023 shows superiority of MIPS compared to medical management on mRS as various time points.

The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial thelancet.com/journals/lance…

Check out this #TopicalReview by Seners et al summarizing the literature on imaging biomarkers in predicting post-EVT ICH. #stroke #AHAJournals ahajournals.org/doi/10.1161/ST… Greg Zaharchuk Jeremy Heit, MD, PhD Benjamin Maïer

First Neuro HFOCT in Europe! What a great pleasure to have this awesome tool In Limoges in EMIS Research lab! A new perpective to image Neurovascular diseases and treatments. CHU de Limoges emis-research.com

Hypertensive encephalopathy in France: high prevalence and unacceptable death, heart failure, ESKD, stroke, dementia rate despite no barrier limiting medical care access: WAKE-UP CALL URGENTLY NEEDED!@valentinmaisons Jean-Baptiste de Fréminville @AngoulvantD ahajrnls.org/3Yi2ixd

Should ischemic stroke patients eligible for EVT also receive IVT if they present directly to an EVT-capable center? Our independent patient data meta-analysis published today @theLancet on behalf of IRIS has some answers🧵⬇️#allEyesOnIRIS authors.elsevier.com/c/1hes5_3CjG8W… #stroke

Honored to present LASTE results SLICE - Worldwide / Next Frontiers / Workshops together with Montpellier Team Cases Caroline Arquizan lapergue Bertrand, MD, PhD. Strong benefit of thrombectomy within 7 hrs in unlimitedly large core.NNT 4.Equal benefit in ASPECTS 0-2 vs 3-5 & lower mortality. No more reasons to exclude pts based on imaging !!

All you ever wanted to know about skull channels in our new review by ⁦Jose A. Mazzitelli⁩ with ⁦⁦Matthias Nahrendorf⁩ and his lab || Skull bone marrow channels as immune gateways to the central nervous system | Nature Neuroscience nature.com/articles/s4159…

⭐️ THE MVP OF #Paris2024 Men's #Basketball ⭐️ LeBron James, United States of America 🇺🇸 👑

Job's finished. #Paris2024 x #Basketball (🧑‍🎨 via PRKR)

This is too 🔥🔥🔥🔥🔥🔥🔥

Just Accepted! 🗞️Impact of time from symptom onset to puncture, and puncture to reperfusion, in endovascular therapy in the late time window (>6 hours) journals.sagepub.com/doi/abs/10.117… Benjamin Maïer

Just Accepted! 🗞️Impact of time from symptom onset to puncture, and puncture to reperfusion, in endovascular therapy in the late time window (>6 hours) journals.sagepub.com/doi/abs/10.117… Benjamin Maïer

#STROKE Simultaneous publication at #ESOC2025 🔴🔵 Following bridging therapy, early fibrinogen depletion coagulopathy (FDC) is a frequent event associated with increased risks of hemorrhage and 3-month mortality. #AHAJournals European Stroke Org ahajrnls.org/4dD0TZN

#ESOC2025 #DETERMINE trial explored an individualized MAP-BP management during EVT vs standard (140-180mmHg) ~69yo. NIHSS 15. 91% conscious sedation ❎The intervention did not result in better mRS at 90d (1ry outcome)

🧠 New data from #DETERMINE trial presented at #ESOC2025: Individualised BP management during mechanical thrombectomy for anterior LVO stroke did not improve 90-day functional outcomes compared to standard care. Key takeaway: current BP protocols remain valid. #StrokeResearch

Individualised blood-pressure management is not superior to standard BP control during thrombectomy, according to DETERMINE trial results presented at #ESOC2025 by Benjamin Maïer - moderator Urs Martin Fischer comments that this area "remains an unanswered question" European Stroke Org

It was a pleasure to present the results of the DETERMINE trial at #ESOC2025 Helsinki! As the INDIVIDUATE and IDEAL trials, the individualized BP management was not superior to the standard BP group. Now waiting for the MIST-BP IPDMA! European Stroke Org Hôpital Fondation Adolphe de Rothschild